Humira Biosimilar Trends and Forecast
The future of the global humira biosimilar market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The global humira biosimilar market is expected to grow with a CAGR of 26.0% from 2024 to 2030. The major drivers for this market are growing prevalence of autoimmune diseases, rising pharmaceutical firms to develop and commercialize biosimilar versions of humira, since the expiration of the patents protecting humira paved the path for the entry of biosimilars, and biosimilars provide a more affordable alternative to the reference biologic medicine.
• Lucintel forecasts that, within the product type category, biosimilar humira (adalimumab) will remain the larger segment over the forecast period.
• Within the distribution channel category, hospital pharmacy will remain the largest segment.
• In terms of regions, North America will remain the largest region over the forecast period due to the expiration of humiraÄX%$%Xs patents, the market for biosimilars is projected to expand in the region.
A more than 150-page report is developed to help in your business decisions.
Emerging Trends in the Humira Biosimilar Market
There are a number of emerging factors that are ‘shaping up’ the GSK Humira biosimilar market. These trends are important for the players as these factors lead to change in the competitive rivalry and the manner in which health care systems operate.
• Market Penetration Becoming High: The Humira biosimilars are penetrating more markets with every supplementary approval that more products are issued. Increasing availability improves access to treatment and encourages lower prices thereby making the treatment itself less expensive. This trend is very important for health systems that are trying to contain the costs while providing effective alternatives.
• Improved & Streamlined Formulation & Delivery: Biosimilar product development is always enhanced by new solutions in formulation and delivery systems that improve the patient experience. There is a trend of companies redesigning devices and formulations to be easier to use, for example, pre-filled syringes which make administration easier. This trend is very important in improving the compliance of treatment by patients.
• Growing Acceptance among Healthcare Providers: Healthcare workers are accepting the use of biosimilars in the treatment of patients thanks to the proven efficacy and safety of these products. The use of educational and awareness programs such as trust-building and other confidence-boosting methods is aimed at increasing the acceptance and recognition of these alternatives in clinical practice. This trend is essential for the adoption of biosimilars and therefore wider growth in the market share.
• Price Competition among Competitors: There is rapid price competition in the market as a result of the emergence of biosimilars. Companies tend to use low prices as an important way of regaining the original product’s market share, which also lessens the cost for the patients. This trend is changing the pricing system in the pharmaceutical industry.
• Regulatory Support and Frameworks: Regulatory agencies around the globe are developing more efficacious biosimilar pathways. Existing guidelines are more reasonable and new products can reach the market faster. This trend encourages innovativeness and competition, thus helping patients access more treatment options.
Emerging trends reveal that a member biosimilars market to Humira is taking shape relatively quicker with more penetration, better formulations, increasing provider acceptance, reasonable pricing, and friendly policies. All these measures are pushing the growth and use of biosimilars that will, in turn, help the patients by increasing their access to effective medicines.
Recent Developments in the Humira Biosimilar Market
The most recent changes in the marketplace for Humira biosimilars demonstrate the achievements of a number of companies and regulatory authorities. Such developments are enhancing the market competition as well as making the drugs available to the targeted patients.
• Approval of Multiple Biosimilars: Numerous Humira biosimilars have received approval in the United States, Europe, and Asia. Amgen, Boehringer Ingelheim, Pfizer, and other companies entered the market with their products and provided patients with more choices of treatment, which pressed the prices. The large volume of approved biosimilars is known to help lower prices and widen the market for people with autoimmune disorders.
• Improved Production Technologies: Improvements in the manufacturing processes of biosimilars are allowing the companies to manufacture the products more effectively and at a lower cost than before. Further, newer bioprocessing technologies and their optimal configurations are increasing yields and decreasing costs. Such improvements are necessary for remaining competitive in the environment where costs play a huge role in the acceptance of the product.
• Steps Being Taken Toward Regulatory Harmonization: There is an increase in the harmonizing of the guidelines for approving biosimilars by the regulatory agencies in different jurisdictions. This trend targets the simplification of the approval procedure and encourages companies’ participation in developing the biosimilars. Increased clarity on regulations facilitates quicker access to the markets and boosts the confidence of the manufacturers and healthcare providers.
• Greater Emphasis on the Patient Education: Organizations are making resources available to extend biosimilar education to patients in order to create biosimilars awareness. These initiatives help in addressing barriers and dispelling fears that inhibit patients from switching from reference biologics to biosimilars. This educational approach is essential in improving compliance, acceptance, and treatment persistence.
• Particular Biosimilar Market Consolidation and Special Collaborations: The collaboration of biotechnological companies with pharmaceutical enterprises and research organizations is responsible for the evolution of the biosimilar Humira novel market. Cooperation makes it rather feasible to pool resources and learn new ways of conducting business, which results in better products. These collaborations are very essential in the reduction of time to market for biosimilars and broadening the scope of the biosimilars available in the market.
These developments in recent years are in-line with growth momentum for the biosimilars market for Humira, since there are many approved products, enhanced manufacturability, regulatory alignments, patient outreach, and partnering. All these factors, in turn, are facilitating improved accessibility and costs, in return enhancing patient care and the healthcare system.
Strategic Growth Opportunities for Humira Biosimilar Market
The Humira biosimilar market is rife with some strategic growth in key applications of the market targeting the ‘who’s who’ of the swelling market. Companies, seeking to guard their stake in the market, tend to seek targetable areas and take advantages of arising trends.
• Expanding Therapeutic Indications: Biosimilars could be deployed to a larger variety of therapeutic claims more than that of just rheumatoid arthritis and psoriasis. The firms ought to focus more on other anti-autoimmune and anti-inflammatory therapeutic ailments to grow their product portfolio. This would help in increasing the market share as well as allowing patients to receive some of the advanced medications.
• Developing Combination Therapies: The use of biosimilars with other forms of therapeutics helps to improve treatment. This is an investment opportunity for the firms to carry out research and innovate such therapies. This may follow new clinical use and may help in making products stand out in a tight market.
• Utilization of Telemedicine and Digital Health: With the increasing adoption of telemedicine, there are chances for organizations to better reach out and educate patients about biosimilars. This makes it easier for them to use a phone or other means of communication to access healthcare on a remote basis, which can also be helpful in managing adherence and compliance and therefore, most people are likely to use and accept the biosimilars.
• Target Emerging Markets: There are great prospects in emerging markets for the growth of Humira biosimilars. As the demand for economical medicines grows as well as the accessibility to healthcare, businesses may wish to consider some parts of Southeast Asia or Latin America to launch their products, thereby increasing their market share.
• Tailored Medicine Approach: Such investment in personalized medicine approaches such as biosimilar patient sub-screening by biomarkers will improve the success of indeterminate biosimilars. Today, it appears that companies competing with the one you describe wish to focus on the individual needs of the patient when developing therapy, and this will enhance their sales.
Such strategic growth opportunities portray the huge potential in Humira biosimilars. It concludes by encouraging companies to broaden their indications, identify opportunities in the development of combinations, go digital, venture into new markets, and practice precision medicine so as to do well in the changing environment.
Humira Biosimilar Market Driver and Challenges
Just as any other market, the Humira biosimilar market is not devoid of various drivers and challenges that affect its growth and development. Such possibilities should be known for successful competition in the market.
The factors responsible for driving the Humira biosimilar market include:
• Patent Expiration of Humira: The patent expiration of Humira has acted as a permissive bulldozer towards the accelerating biosimilar market, hence increasing the competitive edge. This facilitates market entry by numerous companies with their products, which offers cheaper means to the patients and decreases the prices.
• Rising Healthcare Costs: To look for the bottleneck, it’s obvious that the increasing healthcare costs call for the need of safe, cost-effective treatment alternatives like the biosimilars. Given the situation, it is most likely that patients and healthcare providers will use some affordable alternatives such as Humira biosimilars that can control the diseases without loss of effectiveness.
• Regulatory Support: More efficient approval processes for biosimilars are aided by the relevant regulatory patterns. Agencies such as FDDA are trying to formulate policies and offer guidance regarding the elements of the applications, therefore promoting creativity and investment in the biogenetic industry.
• An Increasing Number of Biosimilars Used and Bought: There has been a considerable change in how healthcare professionals and patients perceive biosimilars, in part due to educational campaigns. Once biosimilars are trusted, their use rates will grow, which will be a good thing for growth in the market.
• Technological Advancements: Further development of bioprocessing and formulation technologies is improving the process of creation and manufacture of biosimilars. Such innovations enable producers to efficiently manufacture improved and competitive goods within a very dynamic ambience.
Challenges in the Humira biosimilar market are:
• Market Competition: The competition is fierce with the introduction of numerous biosimilars into the market which will result in competition over pricing and low profitability. There is a need to innovate and position the product strongly in the market at all times.
• Regulatory Complexities: Regardless of advancement, overcoming obstacles associated with achieving biosimilar approvals is still insufficiently resolved. The variation in these requirements across various markets makes it complicated for the companies and even prolongs the market launch.
• Misconceptions about Biosimilars: Public views dishonoring the safety and effectiveness of biosimilars are some of the critical challenges to be tackled. This calls for addressing the public through outreach in order to earn their trust and that of the healthcare providers, which is very important for acceptance.
The expansion of this market is driven by factors such as expiration of Humira patent and the increase in healthcare expenditures. In turn, challenges such as intense competition and increasing complexity in regulation must be considered and solved for positive impact on Humira biosimilars.
List of Humira Biosimilar Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies humira biosimilar companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the humira biosimilar companies profiled in this report include-
• Amgen
• Samsung Bioepis
• Sandoz International
• Mylan
• Boehringer Ingelheim International
• Pfizer
• Fresenius Kabi
• Coherus BioSciences
• Biogen
• AbbVie
Humira Biosimilar by Segment
The study includes a forecast for the global humira biosimilar by product type, patient age, indication, distribution channel, and region.
Humira Biosimilar Market by Product Type [Analysis by Value from 2018 to 2030]:
• Biosimilar Humira (Adalimumab)
• Interchangeable Biosimilar Humira
Humira Biosimilar Market by Patient Age [Analysis by Value from 2018 to 2030]:
• Adult Patients
• Pediatric Patients
• Geriatric Patients
Humira Biosimilar Market by Indication [Analysis by Value from 2018 to 2030]:
• Rheumatoid Arthritis
• Psoriasis
• CrohnÄX%$%Xs Disease
• Ulcerative Colitis
• Ankylosing Spondylitis
• Juvenile Idiopathic Arthritis
Humira Biosimilar Market by Distribution Channel [Analysis by Value from 2018 to 2030]:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
Humira Biosimilar Market by Region [Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Humira Biosimilar Market
Over the last few years, the Humira biosimilar market is getting more intense as patents for AbbVie’s blockbuster drug are expiring allowing other players to rush in. This shift is quite significant for countries including the USA, China, Germany, India, Japan, and others that have different regulatory and market conditions. The introduction of Bio elements strives to create inexpensive alternatives for patients tormented with autoimmune disorders and manufacturers seeking to improve the efficiency and accessibility of their goods. Incorporation of progressed formulation, production methods and regulatory approvals can be expected in relation to the current trends making one appreciate the growth of these emerging markets.
• United States: With respect to the U.S. Humira biosimilar market, the 2023 patent expiration is helping the market gain traction, a few biosimilars have already been approved including AmgenÄX%$%Xs and BoehringerÄX%$%Xs offerings. More biosimilars will join the figures intensifying the competition in the market leading to lower prices and better access on the patients. Competition that would traditionally assist the FDA in pushing more efficient drugs into the market is being advanced by the faster approval time of biosimilars thereby placing rheumatoid arthritis and CrohnÄX%$%Xs patient under more care options.
• China: Biosimilar Market in China is continuing to expand with growing demand and support for bio-equivalence development by the government. Companies like Innocent Biologics, Mepham and others have come up with launching biosimilars of late. There is China-U.S. agreement to lower the prices for medical services. The regulatory agencies in several countries are clear about these regulations, which is purposefully promoting the chances of penetration into the market and increasing the rate of innovation and is assumed to increase the access of patients to important drugs.
• Germany: Germany is the leading country in the market of biosimilars within Europe with Lot of biosimilars of Humira present in the market. The way that the German healthcare sector is structured incentivizes biosimilar the need for insurers and patients to save money. Employees and management have undertaken forward market engagements such as initiating new reimbursement models and conducting health authorizing enabling activities to fast increase the adoption of biosimilars. The positive feedback that has been extended by doctors concerning biosimilars is likely to approval further expansion of the market that has been embraced with the need to control expenses of treatments of autoimmune diseases.
• India: In India, market of Humira b biosimilars is developing as players like Dr. Reddy’s and biologics in the country are developing reasonably priced suitable competition b Biocon come into the market. An upsurge in autoimmune diseases & increasing expenditure on healthcare is driving the growth of these low-cost biopharmaceuticals. Supportive regulatory reforms for the faster approval of biosimilars are boosting the growth of the market. This self-sufficiency on the part of the country to produce biopharmaceuticals is increasing availability of biosimilars at cheaper rates for the Indians and also increasing the status of India in the global biopharmaceuticals market.
• Japan: Japan’s Humira biosimilars market is progressing gradually with in the month of July new biosimilar hill expedite biosimilars where a number of biosimilars approvals since the expirations of the patent. The Government of Japan has motivated the adoption of ‘biosimilar’ products to cut costs on the healthcare system and allow more patients to be treated. Conducting campaigns targeting healthcare practitioners in order to promote the usage of biosimilars and devising schemes to subsidize their consumption are some of the approaches. Given the widening nature of this biosimilars’ acceptance trend, it can be foreseen that the market would grow potentially offering escalating options to caregivers of patients with chronic inflammatory disorders.
Features of the Global Humira Biosimilar Market
Market Size Estimates: Humira biosimilar market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Humira biosimilar market size by various segments, such as by product type, patient age, indication, distribution channel, and region in terms of value ($B).
Regional Analysis: Humira biosimilar market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different product type, patient age, indication, distribution channel, and regions for the humira biosimilar market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the humira biosimilar market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q1. What is the growth forecast for humira biosimilar market?
Answer: The global humira biosimilar market is expected to grow with a CAGR of 26.0% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the humira biosimilar market?
Answer: The major drivers for this market are growing prevalence of autoimmune diseases, rising pharmaceutical firms to develop and commercialize biosimilar versions of humira, since the expiration of the patents protecting humira paved the path for the entry of biosimilars and biosimilars provide a more affordable alternative to the reference biologic medicine.
Q3. What are the major segments for humira biosimilar market?
Answer: The future of the humira biosimilar market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets.
Q4. Who are the key humira biosimilar market companies?
Answer: Some of the key humira biosimilar companies are as follows:
• Amgen
• Samsung Bioepis
• Sandoz International
• Mylan
• Boehringer Ingelheim International
• Pfizer
• Fresenius Kabi
• Coherus BioSciences
• Biogen
• AbbVie
Q5. Which humira biosimilar market segment will be the largest in future?
Answer: Lucintel forecasts that biosimilar humira (adalimumab) will remain the larger segment over the forecast period.
Q6. In humira biosimilar market, which region is expected to be the largest in next 6 years?
Answer: North America will remain the largest region over the forecast period due to the expiration of humiraÄX%$%Xs patents, the market for biosimilars is projected to expand in the region.
Q.7 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the humira biosimilar market by product type (biosimilar humira (adalimumab) and interchangeable biosimilar humira), patient age (adult patients, pediatric patients, and geriatric patients), indication (rheumatoid arthritis, psoriasis, crohnÄX%$%Xs disease, ulcerative colitis, ankylosing spondylitis, juvenile idiopathic arthritis, and others), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Humira Biosimilar Market, Humira Biosimilar Market Size, Humira Biosimilar Market Growth, Humira Biosimilar Market Analysis, Humira Biosimilar Market Report, Humira Biosimilar Market Share, Humira Biosimilar Market Trends, Humira Biosimilar Market Forecast, Humira Biosimilar Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.